[Process in surgical exeresis of colorectal cancer liver metastases].
Liver resection is the only curative option offering long-term survival in patients with colorectal liver metastases (25 to 40% five-year survival). It can be achieved with low mortality and low morbidity. However, this surgical approach can be offered only for approximately 10 to 20% of patients with colorectal liver metastases. Therefore, 80 to 90% of patients are excluded from liver surgery and will receive palliative therapies. Recent advances have selected subgroups of patients presenting initially unresectable disease to achieve curative resection. These new multidisciplinary strategies were developed in order to increase safely the resecability in patients with initially non-resectable liver metastases and to improve treatment of recurrences in patients with isolated liver metastases either by repeat hepatectomies or local tumor destruction. These strategies offer the same survival than observed in patients with initially resectable liver metastases. Our series includes 438 patients operated on for colorectal liver metastases between 1987 and 2002. Overall mortality was 1.1%, morbidity was 26%. Actuarial 5-year and 10-year survival were respectively 29.6% and 20.1%.
Centre de Chirurgie Viscérale et de Transplantation, Hôpital de Hautepierre, Avenue Molière-67098 Strasbourg, France.
Daniel
D
Jaeck
Philippe
P
Bachellier
Jean-Christophe
JC
Weber
Elie
E
Oussoultzoglou
Michel
M
Greget
D000206:Actuarial Analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000098:blood supply / Q000556:secondary* / Q000601:surgery / Q000628:therapy; D017115:Catheter Ablation; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D017679:Cryotherapy; D004621:Embolization, Therapeutic; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000556:secondary* / Q000601:surgery / Q000628:therapy; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D020360:Neoadjuvant Therapy; D011169:Portal Vein; D011300:Preoperative Care; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents